| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatic Stellate Cells | 6 | 2025 | 25 | 3.520 |
Why?
|
| Liver Cirrhosis | 7 | 2025 | 181 | 3.290 |
Why?
|
| RNA, Long Noncoding | 5 | 2025 | 171 | 2.840 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 116 | 1.650 |
Why?
|
| Cell Differentiation | 14 | 2021 | 1386 | 1.630 |
Why?
|
| Transcriptome | 4 | 2025 | 399 | 1.500 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 181 | 1.500 |
Why?
|
| Liver | 5 | 2025 | 871 | 1.140 |
Why?
|
| Embryonic Stem Cells | 5 | 2017 | 154 | 1.130 |
Why?
|
| Smad3 Protein | 3 | 2016 | 17 | 1.000 |
Why?
|
| Fatty Liver | 2 | 2024 | 111 | 0.940 |
Why?
|
| Transcription Factors | 8 | 2023 | 1556 | 0.940 |
Why?
|
| Human Embryonic Stem Cells | 3 | 2020 | 38 | 0.890 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 161 | 0.850 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2024 | 14 | 0.840 |
Why?
|
| Hepatocytes | 2 | 2025 | 222 | 0.830 |
Why?
|
| Endoderm | 2 | 2020 | 47 | 0.760 |
Why?
|
| Software | 1 | 2025 | 400 | 0.710 |
Why?
|
| Cicatrix | 1 | 2022 | 62 | 0.710 |
Why?
|
| Collagen | 2 | 2022 | 135 | 0.660 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2022 | 38 | 0.650 |
Why?
|
| Phase Transition | 1 | 2020 | 23 | 0.650 |
Why?
|
| Adenosine | 2 | 2017 | 78 | 0.620 |
Why?
|
| Gene Expression Regulation | 8 | 2017 | 1630 | 0.600 |
Why?
|
| Genome, Human | 2 | 2020 | 237 | 0.590 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 794 | 0.590 |
Why?
|
| Signal Transduction | 10 | 2024 | 3153 | 0.580 |
Why?
|
| Histones | 2 | 2020 | 494 | 0.540 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 13 | 0.520 |
Why?
|
| Adult Stem Cells | 1 | 2017 | 30 | 0.520 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 19 | 0.510 |
Why?
|
| Ceramides | 1 | 2017 | 24 | 0.510 |
Why?
|
| Goosecoid Protein | 1 | 2016 | 4 | 0.500 |
Why?
|
| Myofibroblasts | 3 | 2025 | 21 | 0.470 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 160 | 0.430 |
Why?
|
| Collagen Type I | 2 | 2025 | 44 | 0.430 |
Why?
|
| Mice | 18 | 2025 | 11119 | 0.420 |
Why?
|
| Interferon-gamma | 5 | 2024 | 574 | 0.410 |
Why?
|
| Interleukin-12 | 3 | 2024 | 127 | 0.410 |
Why?
|
| Humans | 29 | 2025 | 65140 | 0.410 |
Why?
|
| Smad2 Protein | 1 | 2014 | 8 | 0.410 |
Why?
|
| RNA | 2 | 2017 | 426 | 0.410 |
Why?
|
| Sequence Analysis, RNA | 2 | 2025 | 180 | 0.410 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 72 | 0.390 |
Why?
|
| Trans-Activators | 4 | 2002 | 321 | 0.390 |
Why?
|
| Th1 Cells | 3 | 2002 | 171 | 0.380 |
Why?
|
| Mice, Knockout | 6 | 2025 | 2157 | 0.360 |
Why?
|
| Animals | 19 | 2025 | 21345 | 0.310 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2003 | 112 | 0.300 |
Why?
|
| Gastroenterologists | 2 | 2019 | 4 | 0.300 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 32 | 0.290 |
Why?
|
| Macrophages | 2 | 2025 | 1038 | 0.290 |
Why?
|
| HIV-1 | 2 | 2025 | 706 | 0.270 |
Why?
|
| Transcription, Genetic | 3 | 2025 | 907 | 0.270 |
Why?
|
| RNA, Antisense | 2 | 2025 | 50 | 0.270 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 277 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 10 | 2025 | 3485 | 0.250 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2017 | 663 | 0.250 |
Why?
|
| Palliative Care | 2 | 2019 | 249 | 0.240 |
Why?
|
| T-Box Domain Proteins | 5 | 2005 | 38 | 0.240 |
Why?
|
| Atlases as Topic | 1 | 2025 | 14 | 0.230 |
Why?
|
| Methyltransferases | 2 | 2017 | 67 | 0.230 |
Why?
|
| RNA, Messenger | 7 | 2017 | 1574 | 0.230 |
Why?
|
| Virus Latency | 1 | 2025 | 31 | 0.220 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2025 | 49 | 0.220 |
Why?
|
| Molecular Sequence Annotation | 1 | 2025 | 67 | 0.220 |
Why?
|
| Lipid Droplets | 1 | 2025 | 35 | 0.220 |
Why?
|
| Fibrosis | 2 | 2022 | 172 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 312 | 0.210 |
Why?
|
| Glucokinase | 1 | 2023 | 3 | 0.210 |
Why?
|
| RNA, Viral | 1 | 2025 | 266 | 0.200 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 61 | 0.200 |
Why?
|
| Actins | 1 | 2025 | 264 | 0.200 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 119 | 0.200 |
Why?
|
| Machine Learning | 1 | 2025 | 195 | 0.190 |
Why?
|
| Cell Movement | 1 | 2025 | 482 | 0.190 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2022 | 14 | 0.180 |
Why?
|
| Ethers | 1 | 2022 | 17 | 0.180 |
Why?
|
| Spiro Compounds | 1 | 2022 | 12 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2022 | 46 | 0.180 |
Why?
|
| Male | 6 | 2025 | 31047 | 0.180 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 361 | 0.180 |
Why?
|
| DNA-Binding Proteins | 3 | 2002 | 1225 | 0.170 |
Why?
|
| Insulin Resistance | 1 | 2024 | 414 | 0.170 |
Why?
|
| Acid Ceramidase | 1 | 2020 | 1 | 0.160 |
Why?
|
| Acetylation | 1 | 2020 | 121 | 0.160 |
Why?
|
| Lysine | 1 | 2020 | 94 | 0.160 |
Why?
|
| Myoblasts | 1 | 2021 | 64 | 0.160 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 98 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2025 | 981 | 0.150 |
Why?
|
| Protein Domains | 1 | 2020 | 154 | 0.150 |
Why?
|
| Gene Expression | 2 | 2002 | 852 | 0.150 |
Why?
|
| Base Sequence | 4 | 2017 | 1332 | 0.150 |
Why?
|
| Disease Progression | 1 | 2023 | 1220 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 268 | 0.140 |
Why?
|
| Attitude | 1 | 2019 | 100 | 0.140 |
Why?
|
| Half-Life | 2 | 2017 | 81 | 0.140 |
Why?
|
| Advance Care Planning | 1 | 2019 | 68 | 0.140 |
Why?
|
| HIV Infections | 1 | 2025 | 955 | 0.140 |
Why?
|
| Exoribonucleases | 1 | 2017 | 30 | 0.130 |
Why?
|
| Methylation | 1 | 2017 | 130 | 0.130 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2017 | 64 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2019 | 219 | 0.120 |
Why?
|
| RNA Stability | 1 | 2017 | 104 | 0.120 |
Why?
|
| Gastrulation | 1 | 2016 | 17 | 0.120 |
Why?
|
| Exons | 1 | 2017 | 208 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2293 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 79 | 0.120 |
Why?
|
| Cell Lineage | 5 | 2014 | 282 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2017 | 96 | 0.120 |
Why?
|
| DNA Transposable Elements | 1 | 2017 | 160 | 0.120 |
Why?
|
| HeLa Cells | 1 | 2017 | 541 | 0.120 |
Why?
|
| Transcription Initiation Site | 1 | 2016 | 47 | 0.120 |
Why?
|
| Obesity | 1 | 2024 | 1274 | 0.120 |
Why?
|
| Epigenomics | 1 | 2016 | 62 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 148 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 6 | 2003 | 868 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2016 | 199 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 425 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2016 | 261 | 0.110 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 146 | 0.110 |
Why?
|
| Computational Biology | 1 | 2017 | 367 | 0.110 |
Why?
|
| RNA-Binding Proteins | 2 | 2017 | 447 | 0.110 |
Why?
|
| Adenine | 1 | 2014 | 48 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 407 | 0.090 |
Why?
|
| Lymphocyte Activation | 4 | 2003 | 753 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 105 | 0.090 |
Why?
|
| Receptors, Interleukin-12 | 2 | 2002 | 9 | 0.090 |
Why?
|
| Receptors, Interleukin | 2 | 2002 | 38 | 0.090 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 20 | 0.090 |
Why?
|
| MyoD Protein | 1 | 2011 | 45 | 0.090 |
Why?
|
| Antigens, Differentiation | 2 | 2001 | 144 | 0.080 |
Why?
|
| Immunoconjugates | 2 | 2001 | 95 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2005 | 676 | 0.080 |
Why?
|
| RNA Processing, Post-Transcriptional | 3 | 2022 | 103 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2023 | 440 | 0.070 |
Why?
|
| Endothelial Growth Factors | 2 | 1999 | 22 | 0.070 |
Why?
|
| Lymphokines | 2 | 1999 | 67 | 0.070 |
Why?
|
| Female | 4 | 2025 | 34018 | 0.070 |
Why?
|
| Adult | 1 | 2025 | 17358 | 0.070 |
Why?
|
| Th2 Cells | 3 | 2003 | 93 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2188 | 0.060 |
Why?
|
| Cell Line | 3 | 2014 | 2024 | 0.060 |
Why?
|
| Immunologic Memory | 2 | 2005 | 284 | 0.060 |
Why?
|
| Virus Activation | 1 | 2025 | 23 | 0.060 |
Why?
|
| GATA3 Transcription Factor | 2 | 2002 | 16 | 0.060 |
Why?
|
| Interleukin-4 | 2 | 2002 | 147 | 0.050 |
Why?
|
| Receptors, Interferon | 1 | 2024 | 20 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2025 | 157 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2002 | 197 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2023 | 41 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2002 | 302 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 450 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 180 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 1979 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2001 | 398 | 0.050 |
Why?
|
| Nucleosides | 1 | 2022 | 11 | 0.050 |
Why?
|
| Terminal Repeat Sequences | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 2701 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 117 | 0.040 |
Why?
|
| STAT4 Transcription Factor | 1 | 2001 | 7 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2001 | 85 | 0.040 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 15 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 241 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2025 | 641 | 0.040 |
Why?
|
| Cell Fusion | 1 | 2021 | 39 | 0.040 |
Why?
|
| Myofibrils | 1 | 2021 | 20 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2757 | 0.040 |
Why?
|
| Chickens | 1 | 2021 | 94 | 0.040 |
Why?
|
| Glucose | 1 | 2023 | 476 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 213 | 0.040 |
Why?
|
| Chromatin | 2 | 2002 | 641 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 500 | 0.040 |
Why?
|
| Cell Communication | 1 | 2021 | 133 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 299 | 0.040 |
Why?
|
| Alleles | 1 | 2001 | 453 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 380 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 62 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2019 | 18 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2002 | 433 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1999 | 130 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2019 | 55 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 1999 | 102 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2019 | 58 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 896 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 1998 | 36 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 1998 | 42 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 103 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 790 | 0.030 |
Why?
|
| Polyadenylation | 1 | 2016 | 51 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 96 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 201 | 0.030 |
Why?
|
| United States | 2 | 2019 | 8093 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 443 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 13 | 0.030 |
Why?
|
| Stem Cells | 1 | 2016 | 276 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2014 | 173 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2005 | 1290 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 596 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 624 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 518 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 3762 | 0.020 |
Why?
|
| CTLA-4 Antigen | 2 | 2001 | 72 | 0.020 |
Why?
|
| Abatacept | 2 | 2001 | 67 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1038 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2001 | 342 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 1999 | 22 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 1589 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 426 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 1999 | 234 | 0.020 |
Why?
|
| Cytokines | 2 | 2003 | 952 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 2661 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 71 | 0.010 |
Why?
|
| Interleukin-15 | 1 | 2005 | 25 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1999 | 583 | 0.010 |
Why?
|
| Arenaviridae Infections | 1 | 2003 | 15 | 0.010 |
Why?
|
| Granzymes | 1 | 2003 | 22 | 0.010 |
Why?
|
| Perforin | 1 | 2003 | 26 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2003 | 34 | 0.010 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2003 | 88 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 138 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 121 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 96 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 1233 | 0.010 |
Why?
|
| CpG Islands | 1 | 2002 | 219 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 312 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 662 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 663 | 0.010 |
Why?
|
| Leishmania major | 1 | 2000 | 8 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2000 | 22 | 0.010 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2000 | 17 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2000 | 116 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 2000 | 57 | 0.010 |
Why?
|
| Cell Death | 1 | 2001 | 289 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 194 | 0.010 |
Why?
|
| Staurosporine | 1 | 1999 | 19 | 0.010 |
Why?
|
| Transgenes | 1 | 2000 | 204 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1999 | 257 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 391 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1999 | 374 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 165 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1999 | 153 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1999 | 161 | 0.010 |
Why?
|
| Homeostasis | 1 | 2000 | 379 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 700 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 367 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 385 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 1998 | 243 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 414 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 730 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 1008 | 0.010 |
Why?
|
| Melanoma | 1 | 1998 | 333 | 0.010 |
Why?
|